| Literature DB >> 32187554 |
Giorgio Ramadori1, Rafael M Ioris2, Zoltan Villanyi3, Raquel Firnkes2, Olesya O Panasenko4, George Allen3, Georgia Konstantinidou5, Ebru Aras2, Xavier Brenachot2, Tommasina Biscotti6, Anne Charollais2, Michele Luchetti7, Fedor Bezrukov8, Alfredo Santinelli6, Muntaha Samad9, Pierre Baldi9, Martine A Collart10, Roberto Coppari11.
Abstract
Cancer therapy is limited, in part, by lack of specificity. Thus, identifying molecules that are selectively expressed by, and relevant for, cancer cells is of paramount medical importance. Here, we show that peptidyl-prolyl-cis-trans-isomerase (PPIase) FK506-binding protein 10 (FKBP10)-positive cells are present in cancer lesions but absent in the healthy parenchyma of human lung. FKBP10 expression negatively correlates with survival of lung cancer patients, and its downregulation causes a dramatic diminution of lung tumor burden in mice. Mechanistically, our results from gain- and loss-of-function assays show that FKBP10 boosts cancer growth and stemness via its PPIase activity. Also, FKBP10 interacts with ribosomes, and its downregulation leads to reduction of translation elongation at the beginning of open reading frames (ORFs), particularly upon insertion of proline residues. Thus, our data unveil FKBP10 as a cancer-selective molecule with a key role in translational reprogramming, stem-like traits, and growth of lung cancer.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32187554 DOI: 10.1016/j.celrep.2020.02.082
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423